Sevelamer carbonate (Renvela®) | Phase 3 | Kidney Diseases | - |
| Phase 3 | Pancreatic Neoplasms | - |
| Phase 3 | Type 2 Diabetes Mellitus | - |
| Phase 3 | Diabetes Mellitus | - |
A/H1N1 pandemic influenza vaccine (non- adjuvanted) | Phase 3 | Influenza | - |
Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus | Phase 3 | Tetanus | - |
| Phase 3 | Constipation | - |
High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD) | Phase 3 | Influenza Immunization | - |
| Phase 3 | Rheumatoid Arthritis | - |
| Phase 3 | Diphtheria | - |
| Phase 3 | Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus | - |
DTaP-IPV-Hep B-PRP~T combined vaccine | Phase 3 | Diphtheria | - |
| Phase 3 | Major Depressive Disorder | - |
| Phase 3 | Type 2 Diabetes Mellitus | - |
| Phase 3 | Dermatitis Atopic | - |
tolevamer potassium-sodium (GT267-004) | Phase 3 | Clostridium Enterocolitis | - |
| Phase 3 | Type 1 Diabetes Mellitus | - |
| Phase 3 | Osteoarthritis of Shoulder | - |
| Phase 3 | Hypercholesterolemia | - |
Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus | Phase 3 | Dengue | - |
High-Dose Inactivated, Split-Virion Influenza Vaccine | Phase 3 | Orthomyxoviridae Infection | - |
| Phase 3 | Neurodermatitis | - |
Iniparib (SAR240550/BSI-201) | Phase 3 | Solid Tumors | - |
Inactivated, split-virion influenza vaccine | Phase 3 | Orthomyxoviridae Infection | - |
| Phase 3 | Hemophilia | - |
| Phase 3 | Differentiated Thyroid Cancer | - |
| Phase 3 | Chronic Obstructive Pulmonary Disease | - |
| Phase 3 | Mucopolysaccharidosis I | - |
Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative | Phase 3 | Influenza | - |
| Phase 3 | Venous Thromboembolism | - |
epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile | Phase 3 | Breast Neoplasms | - |
| Phase 3 | Type 2 Diabetes Mellitus | - |
| Phase 3 | Deep Venous Thrombosis | - |
| Phase 3 | Hemophilia A | - |
| Phase 3 | Asthma | - |
| Phase 3 | B Cell Chronic Lymphocytic Leukemia | - |
| Phase 3 | RSV Immunization | - |
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine | Phase 3 | Meningococcal Meningitis | - |
Oxaliplatin + 5-Fluorouracil/Leucovorin | Phase 3 | Carcinoma, Hepatocellular | - |
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative | Phase 3 | Influenza | - |
DTaP-IPV combined vaccine | Phase 3 | Pertussis | - |
Low Dose (LD) RSVt vaccine | Phase 3 | RSV Immunisation | - |
| Phase 3 | Diabetes Mellitus, Type 2 | - |
Insulin glargine (HOE901) | Phase 3 | Type 2 Diabetes Mellitus | - |
| Phase 3 | Acquired Thrombotic Thrombocytopenic Purpura | - |
| Phase 3 | Atrial Fibrillation | - |
Granulocyte-colony stimulating factor (G-CSF) | Phase 3 | Non-Hodgkin's Lymphoma | - |
| Phase 3 | Hypercholesterolemia | - |
Riliprubart Prefilled Pen (PFP) | Phase 3 | Polyneuropathy, Inflammatory Demyelinating, Chronic | - |
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL) | Phase 3 | Diphtheria | - |
| Phase 3 | Sleep Initiation and Maintenance Disorders | - |
Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy | Phase 3 | Head and Neck Neoplasms | - |
Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine | Phase 3 | Meningitis | - |
Measles, combinations with mumps and rubella, live attenuated | Phase 3 | Yellow Fever Immunization | - |
| Phase 3 | Thrombosis | - |
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | Phase 3 | Meningitis | - |
| Phase 3 | Hemophilia B | - |
| Phase 3 | Diphtheria | - |
gemcitabine/Eloxatin (GEMOX) | Phase 3 | Carcinoma, Non-Small-Cell Lung | - |
Insulin glargine/lixisenatide fixed ratio combination | Phase 3 | Type 2 Diabetes Mellitus | - |
| Phase 3 | Healthy | - |
efanesoctocog alfa (BIVV001) | Phase 3 | Hemophilia A | - |
| Phase 3 | Type 2 Diabetes Mellitus | - |
| Phase 3 | Venous Thromboembolism | - |
| Phase 3 | Rabies | - |
| Phase 3 | Seasonal Allergic Rhinitis | - |
INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010) | Phase 3 | Type 2 Diabetes Mellitus | - |
Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant. | Phase 3 | Dengue Fever | - |
| Phase 3 | Lichen Simplex Chronicus | - |
| Phase 3 | Gastroenteritis | - |
| Phase 3 | Anxiety Disorders | - |
Dermacyd Breeze Pocket BR (Lactic Acid) | Phase 3 | Hygiene | - |
| Phase 3 | Diabetes Mellitus, Type 2 | - |
| Phase 3 | Head and Neck Squamous Cell Carcinoma | - |
| Phase 3 | Diphtheria | - |
riferminogene pecaplasmid | Phase 3 | Peripheral Vascular Diseases | - |
Quadrivalent Influenza Vaccine | Phase 3 | Influenza | - |
| Phase 3 | Hypercholesterolemia | - |
Granulocyte colony-stimulating factor plus plerixafor | Phase 3 | Lymphoma, Non-Hodgkin | - |
| Phase 3 | Prostatitis | - |
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) | Phase 3 | Tetanus | - |
| Phase 3 | Generalized Anxiety | - |
Irbesartan/Amlodipine (150/5mg) | Phase 3 | Hypertension | - |
| Phase 3 | Fabry Disease | - |
| Phase 3 | Rhinitis Allergic | - |
| Phase 3 | Sleep Initiation and Maintenance Disorders | - |
| Phase 3 | Breast Cancer | - |
| Phase 3 | Immune Thrombocytopenia | - |
DTaP-IPV//PRP~T combined vaccine | Phase 3 | Diphtheria | - |
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate | Phase 3 | Meningitis | - |
| Phase 3 | Primary Progressive Multiple Sclerosis | - |
| Phase 3 | Type 1 Diabetes Mellitus | - |
| Phase 3 | Non Small Cell Lung Cancer | - |
| Phase 3 | Agglutinin Disease, Cold | - |
| Phase 3 | Hypertension | - |
| Phase 3 | Type 2 Diabetes Mellitus | - |
| Phase 3 | Diabetes Mellitus, Type 2 | - |
| Phase 3 | Hypertension | - |
Lipid Modifying Therapy (LMT) | Phase 3 | Hypercholesterolemia | - |
Purified vero rabies vaccine - serum free - VRVg-2 | Phase 3 | Rabies | - |
| Phase 3 | Inappropriate ADH Syndrome | - |
Inactivated Split-virion influenza vaccine | Phase 3 | Orthomyxoviridae Infection | - |
| Phase 3 | Diabetes Mellitus, Type 1 | - |
DTaP IPV HB PRP~T vaccine | Phase 3 | Diphtheria | - |
| Phase 3 | Pneumococcal Infections | - |
| Phase 3 | Lung Cancer | - |
| Phase 3 | Glycogen Storage Disease Type II | - |
| Phase 3 | Obesity | - |
Dermacyd PH_DETINLYN (Lactic Acid) | Phase 3 | Hygiene | - |
Influenza virus vaccine (split virion, inactivated) | Phase 3 | Influenza | - |
MenACYW conjugate vaccine | Phase 3 | Meningococcal Infections | - |
| Phase 3 | Non-small Cell Lung Cancer | - |
SR34006 (idraparinux sodium) Injection | Phase 3 | Pulmonary Embolism | - |
Typhoid Vi polysaccharide | Phase 3 | Salmonella Infections | - |
| Phase 3 | Pain | - |
| Phase 3 | Osteoporosis, Postmenopausal | - |
| Phase 3 | Diphtheria | - |
Mometasone furoate nasal spray (MFNS) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | - |
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine) | Phase 3 | Healthy Volunteers (Meningococcal Infection) | - |
Lantus (Insulin glargine) | Phase 3 | Type 2 Diabetes Mellitus | - |
Dupilumab SAR231893 (REGN668) | Phase 3 | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | - |
fexofenadine/Allegra (M016455) | Phase 3 | Atopic Dermatitis | - |
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine | Phase 3 | Healthy Volunteers (Meningococcal Infection) | - |
| Phase 3 | Atrial Fibrillation | - |
| Phase 3 | Hygiene | - |
DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide | Phase 3 | Diphtheria | - |
Inhaled corticosteroid (ICS) therapy | Phase 3 | Asthma | - |
Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine | Phase 3 | Diphtheria | - |
ChimeriVax-JE, Japanese Encephalitis vaccine | Phase 3 | Encephalitis | - |
Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis) | Phase 3 | Diphtheria | - |
DTaP-HB-PRP~T combined vaccine | Phase 3 | Diphtheria | - |
| Phase 3 | Major Depressive Disorders | - |
| Phase 3 | Pompe Disease (Late-onset) | - |
Alirocumab SAR236553 (REGN727) | Phase 3 | Hypercholesterolaemia | - |
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine | Phase 3 | Meningococcal Immunisation (Healthy Volunteers) | - |
Lipid-Modifying Therapy (LMT) | Phase 3 | Hypercholesterolemia | - |
DTaP-IPV-Hep B-PRP~T vaccine (Batch 1) | Phase 3 | Diphtheria | - |
| Phase 3 | Hygiene | - |
| Phase 3 | Ulcerative Colitis | - |
Insulin glargine/Lixisenatide | Phase 3 | Type 2 Diabetes Mellitus | - |
| Phase 3 | Head and Neck Neoplasms | - |
INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010 | Phase 3 | Type 2 Diabetes Mellitus | - |
Insulin glulisine (HMR1964) | Phase 3 | Diabetes, Type I | - |
| Phase 3 | Hygiene | - |
| Phase 3 | Pneumococcal Immunization | - |
| Phase 3 | Cold Agglutinin Disease | - |
| Phase 3 | Chronic Obstructive Pulmonary Disease | - |
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine) | Phase 3 | Meningococcal Immunisation | - |
| Phase 3 | Myocardial Ischemia | - |
Poliomyelitis Vaccine inactivated | Phase 3 | Poliomyelitis | - |
| Phase 3 | RA | - |
| Phase 3 | Fetal Growth Retardation | - |
| Phase 3 | RSV Immunization | - |
Saredutant succinate (SR48968C) | Phase 3 | Depressive Disorder | - |
| Phase 3 | Hygiene | - |
| Phase 3 | Alzheimer Disease | - |
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus | Phase 3 | Dengue Fever | - |
| Phase 3 | Chronic Spontaneous Urticaria | - |
Yellow fever vaccine (live) | Phase 3 | Yellow Fever Immunization | - |
| Phase 3 | Sleep Initiation and Maintenance Disorders | - |
sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®) | Phase 3 | Chronic Kidney Disease | - |
Euvax B®: Hepatitis B vaccine | Phase 3 | Hepatitis B | - |
| Phase 3 | Influenza | - |
| Phase 3 | Stomach Neoplasm | - |
Placebo to match Tolebrutinib | Phase 3 | Non-relapsing Secondary Progressive Multiple Sclerosis | - |
| Phase 2 | Malaria | - |
| Phase 2 | Obesity | - |
| Phase 2 | Peripheral Arterial Disease | - |
CYD dengue vaccine serotypes (1, 2, 3, 4). | Phase 2 | Dengue Virus | - |
| Phase 2 | Stomach Neoplasms | - |
| Phase 2 | Diphtheria | - |
| Phase 2 | Hodgkin's Disease | - |
| Phase 2 | Colitis Ulcerative | - |
| Phase 2 | Respiratory Syncytial Virus Infection | - |
| Phase 2 | Systemic Lupus Erythematosus | - |
| Phase 2 | Chronic Graft-versus-host-disease | - |
A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®) | Phase 2 | Meningitis | - |
| Phase 2 | Neoplasms, Germ Cell and Embryonal | - |
oxaliplatine / gemcitabine / Vinorelbine | Phase 2 | Non Small Cell Lung Cancer | - |
| Phase 2 | Prostate Cancer | - |
| Phase 2 | Carcinoma, Hepatocellular | - |
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate | Phase 2 | Meningitis | - |
Meningococcal polysaccharide diphtheria toxoid conjugate | Phase 2 | Meningitis | - |
| Phase 2 | Estrogen Receptor Negative (ER-Negative) Breast Cancer | - |
| Phase 2 | Chronic Kidney Disease | - |
Fludarabine Phosphate (Fludara) | Phase 2 | Lymphoma | - |
| Phase 2 | Spinal Cord Injury | - |
Inactivated types 1, 2, and 3 poliovirus, D antigens | Phase 2 | Poliomyelitis | - |
| Phase 2 | Alzheimer Disease | - |
| Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | - |
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Phase 2 | Pulmonary Diseases | - |
Sarilumab SAR153191 (REGN88) | Phase 2 | Juvenile Idiopathic Arthritis | - |
| Phase 2 | Type 1 Diabetes Mellitus | - |
| Phase 2 | Systemic Sclerosis | - |
| Phase 2 | Chlamydia Trachomatis Immunization | - |
Inactivated, split-virion influenza virus | Phase 2 | Influenza | - |
| Phase 2 | Multiple Sclerosis | - |
| Phase 2 | Smoking Cessation | - |
| Phase 2 | Peripheral Arterial Occlusive Disease | - |
| Phase 2 | Hypercholesterolemia | - |
| Phase 2 | Advanced Breast Cancer | - |
Fixed-dose combination of capecitabine and cyclophosphamide SAR439281 | Phase 2 | Breast Cancer Metastatic | - |
| Phase 2 | Endometrial Cancer | - |
| Phase 2 | Hyperuricemia | - |
Allogeneic DCs and Autologous RCC Tumor Derived Cells | Phase 2 | Carcinoma, Renal Cell | - |
| Phase 2 | Influenza | - |
| Phase 2 | Multiple Sclerosis | - |
Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate | Phase 2 | Meningitis | - |
Alemtuzumab plus Fludarabine | Phase 2 | Leukemia, Lymphocytic, Chronic, B-Cell | - |
| Phase 2 | Breast Cancer | - |
| Phase 2 | Pompe Disease (Late-onset) | - |
| Phase 2 | Erectile Dysfunction | - |
| Phase 2 | Nasopharyngeal Neoplasms | - |
High-Dose Trivalent Inactivated Influenza Vaccine | Phase 2 | Influenza | - |
Quadrivalent Influenza mRNA Vaccine MRT5407 | Phase 2 | Influenza Immunization | - |
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1) | Phase 2 | Influenza | - |
| Phase 2 | Primary Peritoneal Cancer | - |
| Phase 2 | Unstable Angina | - |
| Phase 2 | Thyroid Cancer | - |
| Phase 2 | Arrhythmia Prophylaxis | - |
| Phase 2 | Intermittent Claudication | - |
Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28) | Phase 2 | Japanese Encephalitis | - |
| Phase 2 | Acne | - |
| Phase 2 | Uterine Carcinosarcoma | - |
Dupilumab SAR231893/REGN668 | Phase 2 | Asthma | - |
| Phase 2 | Atopic Dermatitis | - |
Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy | Phase 2 | Head and Neck Neoplasms | - |
CYD Dengue Vaccine (5 dose formulation) | Phase 2 | Dengue Fever | - |
| Phase 2 | Acute Urinary Retention | - |
Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb | Phase 2 | Pneumococcal Immunization | - |
Clostridium difficile Toxoid Vaccine | Phase 2 | Clostridium Difficile Infection | - |
| Phase 2 | Multiple Myeloma | - |
| Phase 2 | Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma | - |
| Phase 2 | Diabetes Mellitus, Type 1 | - |
| Phase 2 | Multinodular Goiter | - |
| Phase 2 | Respiratory Syncytial Virus Infection | - |
| Phase 2 | Multiple Sclerosis, Relapsing-Remitting | - |
Docetaxel and cisplatin followed by gemcitabine | Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
| Phase 2 | Microscopic Colitis | - |
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine | Phase 2 | Meningitis | - |
| Phase 2 | Dengue Fever | - |
Live attenuated Japanese encephalitis virus, then ChimeriVax diluent | Phase 2 | Encephalitis | - |
| Phase 2 | Neoplasm Malignant | - |
| Phase 2 | Gaucher Disease, Type 1 | - |
| Phase 2 | Arrhythmia | - |
Placebo (Sodium chloride 0.9%) | Phase 2 | Dengue Fever | - |
| Phase 2 | Alzheimer Disease | - |
| Phase 2 | Geographic Atrophy | - |
| Phase 2 | Head and Neck Neoplasms | - |
SL77.0499-10 (alfuzosin hydrochloride) | Phase 2 | Benign Prostatic Hyperplasia | - |
| Phase 2 | Type 2 Diabetes Mellitus | - |
| Phase 2 | Alpha 1-Antitrypsin Deficiency | - |
| Phase 2 | Crohn's Disease | - |
| Phase 2 | Sjögren's Syndrome | - |
| Phase 2 | Ovarian Cancer | - |
Fabrazyme (agalsidase beta) | Phase 2 | Fabry Disease | - |
Influenza virus vaccine - cell based (2007-2008 Formulation) | Phase 2 | Influenza | - |
| Phase 2 | Overactive Bladder | - |
| Phase 2 | West Nile Fever | - |
| Phase 2 | Systemic Lupus Eythematosus (SLE) | - |
| Phase 2 | Carcinoma, Hepatocellular | - |
Chimeric dengue serotype (1, 2, 3, 4) | Phase 2 | Dengue | - |
| Phase 2 | Prostatic Neoplasms | - |
| Phase 2 | Acute Lymphoblastic Leukemia | - |
| Phase 2 | Rheumatoid Arthritis | - |
Live attenuated Japanese encephalitis virus; Yellow fever virus | Phase 2 | Japanese Encephalitis | - |
| Phase 2 | Breast Cancer | - |
| Phase 2 | Japanese Encephalitis | - |
| Phase 2 | Plasma Cell Myeloma Refractory | - |
| Phase 2 | Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line | - |
| Phase 2 | Lupus Erythematosus, Systemic | - |
VEGF-receptor tyrosine kinase (KDR) | Phase 2 | Multiple Myeloma | - |
High-dose quadrivalent influenza virus vaccine | Phase 2 | Influenza | - |
Swine A/H1N1 influenza vaccine (split virion, inactivated) | Phase 2 | Influenza | - |
| Phase 2 | Rheumatoid Arthritis | - |
A/H5N1 inactivated, split-virion influenza virus | Phase 2 | Influenza | - |
| Phase 2 | Graft vs Host Disease | - |
| Phase 2 | Major Depressive Disorder | - |
Live attenuated Japanese encephalitis virus | Phase 2 | Japanese Encephalitis | - |
| Phase 2 | Ovarian Cancer | - |
| Phase 2 | Lymphoma, Non-Hodgkin | - |
| Phase 2 | Colorectal Cancer | - |
| Phase 2 | Multiple Myeloma | - |
| Phase 2 | Rheumatoid Arthritis | - |
| Phase 2 | Myotonic Dystrophy | - |
RSV vaccine formulation 1 | Phase 2 | Respiratory Syncytial Virus Infection | - |
| Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
Sotagliflozin (SAR439954) | Phase 2 | Diabetes Mellitus | - |
| Phase 2 | Biliary Tract Cancer | - |
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated) | Phase 2 | Influenza | - |
| Phase 2 | Plasma Cell Myeloma | - |
Inactivated, split-virion, influenza virus | Phase 2 | Orthomyxoviridae Infections | - |
| Phase 2 | Osteoarthritis | - |
Yellow fever vaccine (produced on serum-free Vero cells) | Phase 2 | Yellow Fever | - |
